文献速递生殖医学产科

非整倍体植入前遗传学检测:复发性流产与反复种植失败患者活产率的比较

Preimplantation genetic testing for aneuploidy: a comparison of live birth rates in patients with recurrent pregnancy loss due to embryonic aneuploidy or recurrent implantation failure.
PubMed 文献 · Hum Reprod · 2019-01-01

多中心前瞻性预试验纳入171例患者,比较PGT-A与未行PGT-A在因胚胎非整倍体所致复发性流产(RPL)及反复种植失败(RIF)患者中的效果。结果显示PGT-A未提高每患者活产率(RPL组26.8% vs 21.1%,RIF组35.7% vs 26.0%),也未降低临床流产率,但提高了每移植周期活产率并降低了生化妊娠丢失率。

要点

  • PGT-A未改善RPL或RIF患者每患者活产率,也未降低临床流产率。
  • PGT-A提高每移植周期活产率:RPL组52.4% vs 21.6%,RIF组62.5% vs 31.7%。
  • PGT-A降低生化妊娠丢失率:RPL组12.5% vs 45.0%,RIF组10.5% vs 40.9%。

核心结论

  • PGT-A未能提高每患者活产率或降低流产率,在RPL和RIF两组中均如此。
  • PGT-A提高了每移植周期活产率并降低了生化妊娠丢失率。

研究设计与样本

  • 多中心前瞻性预试验,2017年1月至2018年6月招募171例患者。
  • RPL组41例接受PGT-A、38例未接受;RIF组42例接受PGT-A、50例未接受。
  • 每个年龄组(35-36、37-38、39-40或41-42岁)至少选择10名女性进入PGT-A组。
  • 采用滋养层活检和阵列比较基因组杂交(aCGH)进行PGT-A。

主要发现

  • 每患者活产率:RPL组PGT-A 26.8% vs 未PGT-A 21.1%,无显著差异;RIF组35.7% vs 26.0%,无显著差异。
  • 每临床妊娠流产率:RPL组PGT-A 14.3% vs 未PGT-A 20.0%,无差异;RIF组11.8% vs 0%,无差异。
  • 每胚胎移植活产率:RPL组52.4% vs 21.6%(调整OR 3.89;95%CI 1.16-13.1);RIF组62.5% vs 31.7%(调整OR 3.75;95%CI 1.28-10.95)。
  • 每生化妊娠的生化妊娠丢失率:RPL组12.5% vs 45.0%(调整OR 0.14;95%CI 0.02-0.85);RIF组10.5% vs 40.9%(调整OR 0.17;95%CI 0.03-0.92)。
  • RPL与RIF患者的遗传异常分布无差异,但双三体在RPL患者中趋于更常见。

临床怎么用

  • PGT-A虽未提高每患者活产率,但可减少达到相似活产数所需的胚胎移植次数。
  • RPL组中大部分妊娠丢失可能源于非整倍体,因PGT-A降低了该组妊娠丢失的总体发生率。

局限性

  • 样本量太小,无法发现提高每患者活产率和降低每患者临床流产率的显著优势。
  • 需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Can preimplantation genetic testing for aneuploidy (PGT-A) improve the live birth rate and reduce the miscarriage rate in patients with recurrent pregnancy loss (RPL) caused by an abnormal embryonic karyotype and recurrent implantation failure (RIF)? SUMMARY ANSWER: PGT-A could not improve the live births per patient nor reduce the rate of miscarriage, in both groups. WHAT IS KNOWN ALREADY: PGT-A use has steadily increased worldwide. However, only a few limited studies have shown that it improves the live birth rate in selected populations in that the prognosis has been good. Such studies have excluded patients with RPL and RIF. In addition, several studies have failed to demonstrate any benefit at all. PGT-A was reported to be without advantage in patients with unexplained RPL whose embryonic karyotype had not been analysed. The efficacy of PGT-A should be examined by focusing on patients whose previous products of conception (POC) have been aneuploid, because the frequencies of abnormal and normal embryonic karyotypes have been reported as 40-50% and 5-25% in patients with RPL, respectively. STUDY DESIGN, SIZE, DURATION: A multi-centre, prospective pilot study was conducted from January 2017 to June 2018. A total of 171 patients were recruited for the study: an RPL group, including 41 and 38 patients treated respectively with and without PGT-A, and an RIF group, including 42 and 50 patients treated respectively with and without PGT-A. At least 10 women in each age group (35-36, 37-38, 39-40 or 41-42 years) were selected for PGT-A groups. PARTICIPANTS/MATERIALS, SETTING, METHODS: All patients and controls had received IVF-ET for infertility. Patients in the RPL group had had two or more miscarriages, and at least one case of aneuploidy had been ascertained through prior POC testing. No pregnancies had occurred in the RIF group, even after at least three embryo transfers. Trophectoderm biopsy and array comparative genomic hybridisation (aCGH) were used for PGT-A. The live birth rate of PGT-A and non-PGT-A patients was compared after the development of blastocysts from up to two oocyte retrievals and a single blastocyst transfer. The miscarriage rate and the frequency of euploidy, trisomy and monosomy in the blastocysts were noted. MAIN RESULT AND THE ROLE OF CHANCE: There were no significant differences in the live birth rates per patient given or not given PGT-A: 26.8 versus 21.1% in the RPL group and 35.7 versus 26.0% in the RIF group, respectively. There were also no differences in the miscarriage rates per clinical pregnancies given or not given PGT-A: 14.3 versus 20.0% in the RPL group and 11.8 versus 0% in the RIF group, respectively. However, PGT-A improved the live birth rate per embryo transfer procedure in both the RPL (52.4 vs 21.6%, adjusted OR 3.89; 95% CI 1.16-13.1) and RIF groups (62.5 vs 31.7%, adjusted OR 3.75; 95% CI 1.28-10.95). Additionally, PGT-A was shown to reduce biochemical pregnancy loss per biochemical pregnancy: 12.5 and 45.0%, adjusted OR 0.14; 95% CI 0.02-0.85 in the RPL group and 10.5 and 40.9%, adjusted OR 0.17; 95% CI 0.03-0.92 in the RIF group. There was no difference in the distribution of genetic abnormalities between RPL and RIF patients, although double trisomy tended to be more frequent in RPL patients. LIMITATIONS, REASONS FOR CAUTION: The sample size was too small to find any significant advantage for improving the live birth rate and reducing the clinical miscarriage rate per patient. Further study is necessary. WIDER IMPLICATION OF THE FINDINGS: A large portion of pregnancy losses in the RPL group might be due to aneuploidy, since PGT-A reduced the overall incidence of pregnancy loss in these patients. Although PGT-A did not improve the live birth rate per patient, it did have the advantage of reducing the number of embryo transfers required to achieve a similar number live births compared with those not undergoing PGT-A. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by the Japan Society of Obstetrics and Gynecology and grants from the Japanese Ministry of Education, Science, and Technology. There are no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Sato T, Sugiura-Ogasawara M, Ozawa F, et al. Preimplantation genetic testing for aneuploidy: a comparison of live birth rates in patients with recurrent pregnancy loss due to embryonic aneuploidy or recurrent implantation failure. Hum Reprod. 2019. PMID: 31811307. doi:10.1093/humrep/dez229

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。